HAG
ITCI

HighPoint Advisor Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HighPoint Advisor Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,245
Closed -$286K – 697
2024
Q4 		$286K Sell
2,245
-669
-23% -$55K 0.02% 523
2024
Q3 		$252K Buy
2,914
+86
+3% +$6.46K 0.01% 552
2024
Q2 		$221K Sell
2,828
-884
-24% -$61.3K 0.01% 558
2024
Q1 		$246K Buy
3,712
+513
+16% +$35.3K 0.02% 528
2023
Q4 		$217K Buy
+3,199
New +$184K 0.02% 569

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

HighPoint Advisor Group's ITCI Position: Q1 2025 in Review

HighPoint Advisor Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 2,245 shares — an estimated $286K sold.

HighPoint Advisor Group first reported a position in ITCI in Q4 2023 and held it in 5 quarters. The position peaked at $286K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • HighPoint Advisor Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • HighPoint Advisor Group sold 2,245 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $286K.
  • HighPoint Advisor Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 5 quarters.
  • HighPoint Advisor Group's Intra-Cellular Therapies Inc. position peaked at $286K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on HighPoint Advisor Group's 13F filing for Q1 2025, filed 5 May 2025.